US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant strategic investment of $50 million by Japan-headquartered Astellas (TYO: 4503). The investment consists of the purchase of 8,333,333 shares of common stock at $3.00 per share, totaling $25 million, and an additional one-time payment of $25 million for certain strategic rights related to P-MUC1C-ALLO1, a clinical stage program.
Poseida Therapeutics: Advancing Cell and Gene Therapies for Cancer and Rare Diseases
Poseida Therapeutics is a clinical-stage biopharmaceutical company that is advancing differentiated cell and gene therapies with the potential to cure certain cancers and rare diseases. The company’s pipeline encompasses allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates targeting patient populations with high unmet medical needs.
Poseida’s Proprietary Genetic Editing Platforms
The company’s approach to cell and gene therapies is grounded in its proprietary genetic editing platforms, including the non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and nanoparticle and hybrid gene delivery technologies. These platforms enable Poseida to develop innovative therapies that address complex medical challenges.
Global Strategic Collaboration with Roche
Poseida has formed a global strategic collaboration with Roche, aiming to unlock the full potential of cell therapies for patients. This partnership underscores Poseida’s commitment to delivering transformative treatments and strengthening its position at the forefront of cell and gene therapy development.-Fineline Info & Tech
